Cabometyx

Adrenal Medulla, refractory to radioactive iodine treatment, Liver Cancer + 7 more
Treatment
2 FDA approvals
20 Active Studies for Cabometyx

What is Cabometyx

CabozantinibThe Generic name of this drug
Treatment SummaryCabozantinib is a medication used to treat several types of cancer. It was first approved in 2012 and is a type of drug known as a tyrosine kinase inhibitor. The drug is available as the brand name Cometriq and is used to treat metastatic medullary thyroid cancer. In 2016, a capsule formulation called Cabometyx was approved to treat advanced renal cell carcinoma and in 2019 it was approved for the treatment of hepatocellular carcinoma in previously treated patients.
Cometriqis the brand name
image of different drug pills on a surface
Cabometyx Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cometriq
Cabozantinib
2012
10

Approved as Treatment by the FDA

Cabozantinib, also known as Cometriq, is approved by the FDA for 2 uses which include Advanced Renal Cell Carcinoma (aRCC) and Kidney Neoplasms .
Advanced Renal Cell Carcinoma (aRCC)
Used to treat Advanced Renal Cell Carcinoma (aRCC) in combination with Nivolumab
Kidney Neoplasms
Used to treat Advanced Renal Cell Carcinoma (aRCC) in combination with Nivolumab

Effectiveness

How Cabometyx Affects PatientsCabozantinib works by blocking proteins that help cancer cells grow and spread to other parts of the body. It can also stop the growth of new blood vessels that supply tumors with oxygen and nutrients.
How Cabometyx works in the bodyCabozantinib works by blocking specific proteins that help with cell growth and movement. These proteins are called receptor tyrosine kinases and include VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.

When to interrupt dosage

The recommended dosage of Cabometyx is based on the diagnosed condition, including Adrenal Medulla, refractory to radioactive iodine treatment and sorafenib. The quantity of dosage fluctuates depending on the method of administration outlined in the table below.
Condition
Dosage
Administration
Adrenal Medulla
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
refractory to radioactive iodine treatment
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
Liver Cancer
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
Malignant Neoplasms
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
Treatment Naive
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
sorafenib
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
High Risk Patients
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
previously treated with anti-VEGF
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
poor or intermediate risk
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated
Kidney Neoplasms
20.0 mg, , 60.0 mg, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Kit, Tablet, Tablet - Oral, Kit - Oral, Tablet, film coated - Oral, Tablet, film coated

Warnings

Cabometyx Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Cabozantinib may interact with Pulse Frequency
There are 20 known major drug interactions with Cabometyx.
Common Cabometyx Drug Interactions
Drug Name
Risk Level
Description
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Cabozantinib.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Cabozantinib.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Cabozantinib.
Erlotinib
Major
The metabolism of Erlotinib can be decreased when combined with Cabozantinib.
Fluorouracil
Major
The metabolism of Fluorouracil can be decreased when combined with Cabozantinib.
Cabometyx Toxicity & Overdose RiskCabozantinib can cause serious and potentially deadly complications such as abdominal fistulas, perforations, coughing up blood, and internal bleeding from the gastrointestinal tract.
image of a doctor in a lab doing drug, clinical research

Cabometyx Novel Uses: Which Conditions Have a Clinical Trial Featuring Cabometyx?

151 active clinical trials are currently assessing the potential of Cabometyx to treat individuals who have already received anti-VEGF or sorafenib therapy, as well as High Risk Patients.
Condition
Clinical Trials
Trial Phases
previously treated with anti-VEGF
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Treatment Naive
0 Actively Recruiting
High Risk Patients
1 Actively Recruiting
Phase 2
sorafenib
0 Actively Recruiting
refractory to radioactive iodine treatment
0 Actively Recruiting
Liver Cancer
17 Actively Recruiting
Phase 2, Phase 4, Phase 1, Not Applicable, Phase 3
Kidney Neoplasms
12 Actively Recruiting
Not Applicable, Phase 2, Phase 1
poor or intermediate risk
0 Actively Recruiting
Adrenal Medulla
0 Actively Recruiting

Cabometyx Reviews: What are patients saying about Cabometyx?

5Patient Review
10/2/2017
Cabometyx for Cancer Involving the Kidney Cells
I got red spots on my arms and a little bit of diarrhea and vomiting. This medication also caused me to lose weight, which was an unexpected but welcomed side effect.
4.7Patient Review
1/9/2019
Cabometyx for Cancer Involving the Kidney Cells
I've only been taking this treatment for two months and it's already working better than the four months I spent on opdivo. My tumors have shrunk, though there are some nasty side effects that come with it, like intense pain and blisters on my feet.
4.3Patient Review
9/7/2019
Cabometyx for Cancer Involving the Kidney Cells
I've only been taking this medication for 35 days and I've already seen a decrease in the size of my spots. In fact, one spot in my lungs went from 1.3 cm to 0.8 cm! The only downside is the fatigue I experience; though, it's worth noting that I have a full-time job with a lot of stress.
4.3Patient Review
12/31/2020
Cabometyx for Cancer Involving the Kidney Cells
So far, Cabometyx is looking promising.
4Patient Review
8/1/2017
Cabometyx for Cancer Involving the Kidney Cells
I had some pretty severe sores on my feet and fingers, but this treatment helped to clear them up quickly.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cabometyx

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long do you take Cabometyx for?

"Cabometyx is usually taken intravenously every 2 or 4 weeks, with nivolumab treatment lasting up to 2 years if it is decided that it is safe and effective for the patient by both the patient and doctor."

Answered by AI

What is Cabometyx used for?

"Cabozantinib is a medication used to treat advanced renal cell carcinoma."

Answered by AI

What is the success rate of Cabometyx?

"of participants receiving cabozantinib had their tumors shrink during treatment, compared with of those receiving sunitinib. people receiving cabozantinib (5%) had their tumors disappear entirely during treatment, known as a complete response."

Answered by AI

Is Cabometyx chemotherapy or immunotherapy?

"Cabometyx is a chemotherapy drug used to treat patients with advanced renal cell carcinoma and hepatocellular carcinoma. Cabometyx is used as a first-line treatment in combination with Opdivo for patients with advanced renal cell carcinoma. Cabometyx is also used for patients with hepatocellular carcinoma who have previously been treated with Nexavar."

Answered by AI

Clinical Trials for Cabometyx

Image of Dartmouth HItchcock Medical Center in Lebanon, United States.

Computer-Assisted Microwave Ablation for Liver Cancer

18 - 90
All Sexes
Lebanon, NH
The goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults. The employed software calculates and displays a simulation of the ablation such that the physician can visualize what portion of the target tumor has, and has not been treated at any point during the procedure. The main questions it aims to answer are: 1) Does the use of the computer guidance software reduce the number of times a tumor is incompletely treated. 2) Does the use of the computer guidance software reduce the rate of local tumor recurrence at 2 year follow-up? 3) Was there an increase or a decrease in medical problems for participants after a procedure where the guidance software was used? Researchers will compare liver tumor treatment using the computer guidance software with an historic control to see if the addition of the guidance software improved the outcomes after an ablation. Participants will: Undergo CT-guided microwave ablation treatment of a liver tumor using computer-assisted simulation. Visit the clinic at one month and then every 3 months for blood tests and a contrast-enhanced CT or MRI imaging study (as per standard of care)
Waitlist Available
Has No Placebo
Dartmouth HItchcock Medical CenterAndrea Borsic, PHDNE Scientific INC
Image of City of Hope Medical Center in Duarte, United States.

RP2 + Tivozanib for Kidney Cancer

18+
All Sexes
Duarte, CA
This phase II trial tests the effect of RP2 and tivozanib in treating patients with renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing, spreading, or getting worse (progressive) after receiving immunotherapy with immune checkpoint inhibitors (ICIs). RP2 is a herpes simplex virus (a viral infection commonly known as the "cold sore virus") that has been changed to infect and destroy tumor cells and to activate (turn on) the human immune system to attack the tumor cells. Tivozanib hydrochloride blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Tivozanib hydrochloride is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Giving RP2 and tivozanib may be safe, tolerable, and/or effective in treating patients with metastatic renal cell cancer that has progressed after receiving immunotherapy with ICIs.
Phase 2
Waitlist Available
City of Hope Medical Center (+1 Sites)Charles B Nguyen
Image of University of Hawai'i Cancer Center in Honolulu, United States.

Ipilimumab + Nivolumab with SBRT for Liver Cancer

18+
All Sexes
Honolulu, HI
Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally, with Native Hawaiian and Pacific Islander (NHPI) populations experiencing significantly higher mortality rates compared to other groups in Hawaii. This disparity is influenced by factors such as higher prevalence of chronic hepatitis B, non-alcoholic fatty liver disease, limited access to early detection, and delayed diagnoses. NHPI patients are also underrepresented in clinical trials, limiting the relevance of treatment advances for this population. The standard treatment for HCC is surgical resection; however, many NHPI patients present with unresectable disease. Recent advances with immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab, have shown promise in treating advanced HCC and improving survival in previously untreatable cases. Additionally, stereotactic body radiotherapy (SBRT) has been shown to enhance survival and local control when combined with systemic therapies like ICIs. However, without surgery, outcomes remain suboptimal, with response rates for ICIs alone at 20-30%, and combination ICI-SBRT treatment showing slightly better results but still a high risk of progression. Despite improvements in HCC treatment, significant gaps remain in managing borderline resectable disease, especially in NHPI patients. This study aims to evaluate the safety and efficacy of combining ICIs and SBRT with curative surgery for patients with borderline resectable HCC, focusing on NHPI populations. The study will also explore the use of biomarkers such as cell-free DNA (cfDNA), CD8+ T-cell infiltration, and serum cytokine markers to guide personalized treatment strategies. Preliminary findings suggest that this multimodal approach may improve outcomes and enable surgical resection for patients previously considered inoperable. This study seeks to address the unmet need for effective treatment strategies in borderline resectable HCC and to improve survival outcomes for underserved NHPI populations.
Phase 1
Waitlist Available
University of Hawai'i Cancer CenterJared D Acoba, MD
Have you considered Cabometyx clinical trials? We made a collection of clinical trials featuring Cabometyx, we think they might fit your search criteria.Go to Trials
Image of Juravinski Hospital in Hamilton, Canada.

Radiation and Immunotherapy for Liver Cancer

18+
All Sexes
Hamilton, Canada
The objectives of this study is to estimate the biological activity of combination chemotherapy and radiation versus radiation alone in patients with Hepato Cellular Carcinoma (HCC). The study hypothesizes is that combination chemotherapy and radiation is superior to radiation alone in inducing a biological response. The study hypothesizes that combination chemotherapy and radiation is superior to radiation alone in inducing a biological response. A biological response, or change in the tumor microenvironment (TME), is defined by reduced infiltration of intra-tumoral regulatory T cells (Tregs), a decrease in tumour-associated macrophages (TAMs) of the M2 phenotype, and an increase in immune cells such as effector CD8+ T-cells. An increased rate of biological response is therefore expected in participants receiving the combination of Durvalumab, Tremelimumab, and stereotactic body radiation therapy (SBRT), compared to those receiving SBRT alone. Additionally, biological response is hypothesized to correlate with pathological response. The study has been conducted within a WOO window of opportunity randomized clinical trial in order to obtain data in the quickest and safest manner. Patients undergoing surgery are very healthy by definition and will be able to tolerate treatment without any major complications, leading to adequate tissue samples before and after treatment.
Phase 3
Waitlist Available
Juravinski Hospital
Image of University of Oklahoma Health Sciences Center in Oklahoma City, United States.

Multi-Cancer Detection Test for Cancer

45 - 75
All Sexes
Oklahoma City, OK
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).
Recruiting
Has No Placebo
University of Oklahoma Health Sciences Center (+34 Sites)Scott D Ramsey
Image of Centre Hospitalier de l'Université de Montréal in Montreal, Canada.

Portal + Hepatic Vein Embolization for Liver Cancer

18+
All Sexes
Montreal, Canada
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma. The main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who become resectable within 3 weeks and improves 5-year overall survival compared to PVE alone by enhancing liver hypertrophy. Participants will: * Undergo either standard PVE or combined PVE and HVE. * Have regular imaging to assess liver resectability. * Be monitored for survival outcomes up to 5 years after intervention.
Recruiting
Has No Placebo
Centre Hospitalier de l'Université de Montréal (+18 Sites)
Have you considered Cabometyx clinical trials? We made a collection of clinical trials featuring Cabometyx, we think they might fit your search criteria.Go to Trials
Image of Toronto General Hospital in Toronto, Canada.

Radiotherapy + Immunotherapy for Liver Cancer

18 - 70
All Sexes
Toronto, Canada
The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation. The main questions it aims to answer are: * How many patients will achieve transplant with this treatment strategy? * What will the 5-year survival and recurrence-free survival rates be for these patients? Participants will: * Undergo a biopsy of the tumor. * Receive locoregional therapy (SBRT or Y90) followed by immunotherapy (atezolizumab and bevacizumab) 2 to 6 weeks later, for a maximum of 9 months. * Be referred for a liver transplant and undergo the procedure if deemed eligible and safe. * If applicable, be followed for five years post-transplant with regular data collection.
Phase 1 & 2
Recruiting
Toronto General Hospital (+1 Sites)Gonzalo Sapisochin, MD, PhD, MSc
Image of City of Hope Medical Center in Duarte, United States.

CBM588 + Nivolumab + Ipilimumab for Advanced Kidney Cancer

18+
All Sexes
Duarte, CA
This phase I trial tests the safety, side effects, best dose, and effectiveness of CBM588 in combination with nivolumab and ipilimumab in treating patients with kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). CBM588 is a live biotherapeutic that may help improve the effects of immunotherapy. Nivolumab and ipilimumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread by enhancing the ability of the body's immune cells to attack tumor cells. CBM588 in combination with nivolumab and ipilimumab may be safe, tolerable, and/or effective in treating patients with advanced stage kidney cancer.
Phase 1
Recruiting
City of Hope Medical CenterAlex Chehrazi-Raffle, MDOsel, Inc.
Have you considered Cabometyx clinical trials? We made a collection of clinical trials featuring Cabometyx, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security